Puma Biotechnology Inc (PBYI): Price and Financial Metrics

Puma Biotechnology Inc (PBYI): $2.72

0.05 (-1.81%)

POWR Rating

Component Grades








Add PBYI to Watchlist
Sign Up

Industry: Biotech




#19 of 359

in industry

PBYI Price/Volume Stats

Current price $2.72 52-week high $5.16
Prev. close $2.77 52-week low $2.08
Day low $2.71 Volume 73,400
Day high $2.89 Avg. volume 246,853
50-day MA $3.48 Dividend yield N/A
200-day MA $3.54 Market Cap 129.23M

PBYI Stock Price Chart Interactive Chart >


  • Value is the dimension where PBYI ranks best; there it ranks ahead of 99.33% of US stocks.
  • The strongest trend for PBYI is in Stability, which has been heading up over the past 177 days.
  • PBYI's current lowest rank is in the Momentum metric (where it is better than 3.78% of US stocks).

PBYI Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for PBYI is 7.57 -- better than 94.86% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 8.18 for PUMA BIOTECHNOLOGY INC; that's greater than it is for 85.86% of US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, PUMA BIOTECHNOLOGY INC is reporting a growth rate of -148.49%; that's higher than just 9.64% of US stocks.
  • Stocks that are quantitatively similar to PBYI, based on their financial statements, market capitalization, and price volatility, are CSGS, SCWX, MDRX, PLTK, and INTZ.
  • PBYI's SEC filings can be seen here. And to visit PUMA BIOTECHNOLOGY INC's official web site, go to www.pumabiotechnology.com.

PBYI Valuation Summary

  • PBYI's price/sales ratio is 0.6; this is 68.42% lower than that of the median Healthcare stock.
  • Over the past 139 months, PBYI's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for PBYI.

Stock Date P/S P/B P/E EV/EBIT
PBYI 2023-09-22 0.6 4.5 -56.3 17.1
PBYI 2023-09-21 0.6 4.5 -56.5 17.2
PBYI 2023-09-20 0.6 4.5 -56.5 17.2
PBYI 2023-09-19 0.6 4.7 -58.1 17.5
PBYI 2023-09-18 0.6 4.7 -58.6 17.6
PBYI 2023-09-15 0.6 4.8 -59.6 17.8

PBYI Growth Metrics

    The 4 year cash and equivalents growth rate now stands at -15.69%.
  • Its 3 year cash and equivalents growth rate is now at 20.35%.
  • Its 2 year cash and equivalents growth rate is now at -30.71%.
PBYI's revenue has moved down $54,547,000 over the prior 33 months.

The table below shows PBYI's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 217.713 -28.945 9.832
2022-06-30 206.856 -35.706 -34.48
2022-03-31 200.722 -21.906 -48.957
2021-12-31 253.155 20.65 -29.126
2021-09-30 250.355 20.45 -48.244
2021-06-30 254.864 11.672 -35.035

PBYI's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • PBYI has a Quality Grade of C, ranking ahead of 66.91% of graded US stocks.
  • PBYI's asset turnover comes in at 1.012 -- ranking 23rd of 682 Pharmaceutical Products stocks.
  • ACAD, TVTX, and CTMX are the stocks whose asset turnover ratios are most correlated with PBYI.

The table below shows PBYI's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 1.012 0.749 -0.448
2021-06-30 0.995 0.755 -0.266
2021-03-31 1.058 0.780 -0.137
2020-12-31 0.905 0.825 -0.449
2020-09-30 0.955 0.836 -0.355
2020-06-30 1.008 0.842 -0.212

PBYI Price Target

For more insight on analysts targets of PBYI, see our PBYI price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $8.63 Average Broker Recommendation 2.06 (Hold)

Puma Biotechnology Inc (PBYI) Company Bio

Puma Biotechnology is a development stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of products for the treatment of various forms of cancer. The company was founded in 2010 and is based in Los Angeles, California.

PBYI Latest News Stream

Event/Time News Detail
Loading, please wait...

PBYI Latest Social Stream

Loading social stream, please wait...

View Full PBYI Social Stream

Latest PBYI News From Around the Web

Below are the latest news stories about PUMA BIOTECHNOLOGY INC that investors may wish to consider to help them evaluate PBYI as an investment opportunity.

Puma's (PBYI) Alisertib Gets FDA's Orphan Drug Tag for SCLC

Puma's (PBYI) alisertib receives the Orphan Drug designation from the FDA for treating patients with small cell lung cancer.

Yahoo | September 22, 2023

Puma Biotechnology Receives FDA Orphan Drug Designation for Alisertib for the Treatment of Small Cell Lung Cancer

LOS ANGELES, September 21, 2023--The FDA has granted Orphan Drug Designation to Puma Biotechnology's drug candidate alisertib for the treatment of small cell lung cancer.

Yahoo | September 21, 2023

Puma Biotechnology to Present at the H.C. Wainwright 25th Annual Global Investment Conference

LOS ANGELES, August 31, 2023--Alan Auerbach, CEO of Puma Biotechnology, will present a corporate update at the H.C. Wainwright Global Investment Conference beginning on 9/11/23.

Yahoo | August 31, 2023

Puma Biotechnology Announces FDA Clearance of IND for Alisertib in Small Cell Lung Cancer

LOS ANGELES, August 08, 2023--Puma has been notified by the FDA that its IND has been reviewed, and Puma can proceed with clinical development of alisertib monotherapy for SCLC.

Yahoo | August 8, 2023

Puma Biotech (PBYI) Q2 Earnings Beat, Nerlynx Sales Outperform

Puma Biotechnology (PBYI) beats second-quarter earnings and sales estimates. Stock rises in after-hours.

Yahoo | August 4, 2023

Read More 'PBYI' Stories Here

PBYI Price Returns

1-mo -26.68%
3-mo -17.07%
6-mo -5.23%
1-year 19.82%
3-year -72.24%
5-year -94.06%
YTD -35.70%
2022 39.14%
2021 -70.37%
2020 17.26%
2019 -57.00%
2018 -79.41%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!